Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
TRIZIVIR |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nucleoside analogues (reverse transcriptase inhibitors). |
| Generic Name |
|
Abacavir (as sulfate) 300mg, lamivudine 150mg, zidovudine 300mg; tabs. |
| Indications |
|
HIV-1 infection. |
| Children |
|
Not recommended. |
| Adults |
|
<40kg: not recommended. ≥40kg: 1 tab twice daily. |
| Contraindications |
|
See literature regarding fatal hypersensitivity reactions (which may include fever, rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, or respiratory symptoms); discontinue as soon as suspected; do not restart. Hepatic impairment. |
| Precautions |
|
Renal dysfunction (CrCl <50mL/min): not recommended. Suspend if clinical or lab findings of lactic acidosis or hepatotoxicity with steatosis occurs (female gender, obesity, prolonged exposure to nucleosides may increase risk). If abacavir is stopped for reasons other than hypersensitivity, restart only if medical care can be readily accessed by patient or caregiver; monitor for hypersensitivity. Bone marrow depression. Anemia. Hepatitis B. Decompensated liver disease. Risk factors for liver disease. Monitor blood counts. Not for use with other abacavir, lamivudine, zidovudine, emtricitabine, or tenofovir products. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Avoid zalcitabine, stavudine, doxorubicin, ribavirin. Abacavir may antagonize methadone. TMP/SMX, nelfinavir may increase lamivudine levels. Ethanol may increase abacavir levels. Atovaquone, fluconazole, methadone, nelfinavir, probenecid, ritonavir, valproic acid may affect zidovudine levels; monitor. Increased hematologic toxicity with ganciclovir, other bone marrow suppressants or cytotoxic agents. Triple therapy (once daily regimen) with tenofovir or with didanosine + tenofovir: high rate of early viral non-response (see literature). Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin. |
| Adverse Reactions |
|
GI upset, anorexia, insomnia, lab abnormalities (anemia, neutropenia, elevated liver enzymes and CPK, mild hyperglycemia, elevated triglycerides), headache, malaise, myopathy, myositis, neuropathy, lactic acidosis, severe hepatomegaly with steatosis, hypersensitivity reactions (may be fatal), nasal symptoms, cough, fever/chills, depression, fat redistribution, rash (may be severe, eg, Stevens-Johnson), dizziness, myalgia, arthralgia, post-treatment exacerbation of hepatitis, immune reconstitution syndrome. |
| Extra Text |
|
Note: Register pregnant patients exposed to Trizivir by calling (800) 258-4263. Register patients who have had a hypersensitivity reaction to abacavir by calling (800) 270-0425. |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
